Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Single-Institution, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM 02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.

Next Previous
Trial Profile

A Phase I Single-Institution, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM 02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elisidepsin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PharmaMar

Most Recent Events

  • 13 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 13 Jun 2011 Planned end date changed from 1 Sep 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
  • 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top